Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Omni Medique is a specialist regenerative hair and scalp clinic providing non-surgical hair restoration and scalp treatment ...

NOW the sun is out, your SPF should be too. Did you know we are recommended to use two shot glasses worth of suncream to cover our body? It might seem excessive, but no patch should be left ...

Using a dermaroller for hair growth helps you boost length, thickness, and density. Here, learn exactly how to do it, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

How does one live with psoriasis? From medication to nutrition (and beyond), Olivia Marks goes in search of clear answers.

Please provide your email address to receive an email when new articles are posted on . Icotrokinra showed rapid efficacy among adults and adolescents with at least moderate psoriasis. Most ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis ... skin inflammation model after oral dosing. "High-impact skin sites affected by psoriasis can be very challenging ...

Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid ... was reported as early as 24 hours after the first application, with 65.3 ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase ... Beginning 7 days before the baseline visit and throughout the 8-week ...